November 24, 2025 — Leads & Copy — Biomea Fusion, Inc. (Nasdaq: BMEA) will participate in two upcoming investor conferences, the company announced today.
Biomea will attend the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, NY. At the conference, Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings.
The company will also participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Coral Gables, FL, where it will participate in a Fireside Chat at 7:30 AM (EST) and in one-on-one meetings.
Audio webcasts of the presentations will be available here or on the News & Events Page under the Investors & Media section of Biomea’s website. Replays of the webcasts will be available after the live events.
Biomea Fusion is a biopharmaceutical company focused on developing oral small molecule therapies for diabetes and obesity. Its pipeline includes icovamenib, a selective menin inhibitor for diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist for obesity. These programs target cardiometabolic disorders, which affect nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients with diabetes, obesity, and related conditions.
The company’s goal is to find cures for these conditions.
Meichiel Jennifer Weiss, Sr. Director of Investor Relations and Corporate Development, can be reached at ir@biomeafusion.com.
Source: Biomea Fusion
